您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Trastuzumab deruxtecan
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Trastuzumab deruxtecan
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1826843-81-5
包装与价格:
包装价格(元)
1mg (10mg/mL * 100 μL in Aqueous solution)电议
5mg (10mg/mL * 100 μL in Aqueous solution)电议

产品介绍
Trastuzumab deruxtecan (DS-8201a)(溶液)是一种抗人表皮生长因子受体 2 (HER2) 抗体-药物偶联物 (ADC)。曲妥珠单抗 deruxtecan 由人源化抗 HER2 抗体、可酶切肽接头和拓扑异构酶 I 抑制剂组成。 Trastuzumab deruxtecan可用于HER2阳性乳腺癌和胃癌的研究。
Cas No.1826843-81-5
别名DS-8201 (solution); DS-8201a (solution)
Canonical SMILES[Trastuzumab deruxtecan]
储存条件Solution, -20℃, 2 years
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].

Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC50 of 109.7 pM[2].Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐ egative MDA‐MB‐468 cells[2]. Cell Viability Assay[2] Cell Line: KPL‐4 and MDA‐MB‐468 cells

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐ egative tumors under the co‐inoculated condition[2].Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model[3]. Animal Model: Female BALB/c nude mice injected with NCI‐N87 and MDA‐MB‐468‐Luc cells[2]

[1]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. [2]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [3]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.